Flawed ivermectin preprint highlights challenges of COVID drug studies
Abstract
The study's withdrawal from a preprint platform deals a blow to the anti-parasite drug's chances as a COVID treatment, researchers say.
- Publication:
-
Nature
- Pub Date:
- August 2021
- DOI:
- 10.1038/d41586-021-02081-w
- Bibcode:
- 2021Natur.596..173R